Evidence map›Paper›PMID 39279889›Full record

ArticleSurgery open science2024

Analysis of neoadjuvant therapy effect on 30-day postoperative outcomes in gallbladder cancer.

Nicole Martin, Areg Grigorian, Francesca A Kimelman, Zeljka Jutric, Stephen Stopenski, David K Imagawa, Ron F Wolf, Shimul Shah, Jeffry Nahmias

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicole MartinUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.
Areg GrigorianUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.
Francesca A KimelmanUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.
Zeljka JutricUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.
Stephen StopenskiUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.
David K ImagawaUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.
Ron F WolfUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.
Shimul ShahUniversity of Cincinnati, Department of Surgery, 231 Albert Sabin Way, Cincinnati, OH, USA.
Jeffry NahmiasUniversity of California, Irvine, Department of Surgery, 101 The City Dr S, Orange, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The role of neoadjuvant therapy (NAT) in gallbladder cancer (GBC) is not well established. We sought to evaluate the effect of NAT on postoperative outcomes following surgical resection of GBC. We hypothesized that patients receiving NAT would have similar rates of 30-day mortality, readmission, and postoperative complications (e.g. bile leakage and liver failure) compared to those who did not receive NAT. Methods: The 2014-2017 American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Procedure-Targeted Hepatectomy database was queried for patients that underwent surgery for GBC. Propensity scores were calculated to match patients in a 1:2 ratio based on age, comorbidities, functional status, and tumor staging. Results: A total of 37 patients undergoing NAT were matched to 74 patients without NAT. There was no difference in any matched characteristics. Compared to the NAT group, the no NAT cohort had similar rates of postoperative bile leakage (NAT 13.5 % vs. no NAT 10.8 %, Conclusion: In patients undergoing surgical resection for GBC, those with and without NAT had similar rates of readmission and 30-day mortality, however NAT was associated with an increased risk for transfusion. Despite use of a large national database, this study may be underpowered to adequately assess the effect of NAT on perioperative GBC outcomes and thus warrants further investigation.

Indexed as

Blood transfusionGallbladder neoplasmsNeoadjuvant therapyPostoperative complicationsTreatment outcome

Identifiers

PMID39279889
PMCPMC11402315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.